SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required)
Funding Opportunity PAR-20-130 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may includ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 10, 2020 Category: Research Source Type: funding
Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)
Funding Opportunity RFA-HL-21-003 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seeks highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. App...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 2, 2020 Category: Research Source Type: funding
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
Funding Opportunity PAR-20-111 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-541. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project w...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 3, 2020 Category: Research Source Type: funding
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
Funding Opportunity PAR-20-122 from the NIH Guide for Grants and Contracts. Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their pr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 3, 2020 Category: Research Source Type: funding
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional)
Funding Opportunity PAR-20-118 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to accelerate innovative drug and device therapies translation from discovery to early human studies. Studies responsive to this FOA will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early-stage human studi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 25, 2020 Category: Research Source Type: funding
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U19 Clinical Trial Optional)
Funding Opportunity PAR-20-119 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, substance use disorders (SUDs) or alcohol use disorder (AUD); develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders, SUDs or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devic...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 25, 2020 Category: Research Source Type: funding
HEAL Initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development (R61/R33 - Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-20-031 from the NIH Guide for Grants and Contracts. This FOA invites applications for pre-clinical research to stimulate the development of novel, mechanism-based pharmacotherapies to selectively reverse breathing suppression produced by opioids. Two critical phases of pre-clinical investigation are supported. Phase I: the identification and rigorous validation of candidate targets; Phase II: development of therapeutic candidates, such as small molecules, biologics, and natural products that modulate validated targets identified in Phase I, using relevant animal models or human cells/tissue. S...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 24, 2020 Category: Research Source Type: funding
Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)
Funding Opportunity RFA-HL-20-030 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seeks highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. App...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 14, 2019 Category: Research Source Type: funding
Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)
The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seeks highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications submitted in response to this bi-phasic, milestone-driven cooperative ag...
Source: NIDDK Funding Opportunities - August 14, 2019 Category: Endocrinology Source Type: funding
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Required
Funding Opportunity PAR-19-335 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may includ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 5, 2019 Category: Research Source Type: funding
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed
Funding Opportunity PAR-19-333 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may includ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 5, 2019 Category: Research Source Type: funding
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from small business concerns (SBCs) to the newly re-authorized Commercialization Readiness Pilot (CRP) program. The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R and D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)-enabli...
Source: NIDDK Funding Opportunities - August 5, 2019 Category: Endocrinology Source Type: funding
Biological Testing Facility Access For Contraceptive Development (X01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-263 from the NIH Guide for Grants and Contracts. The NICHD has a state-of-the art Biological Testing Facility for advancing male and/or female non-hormonal contraception development with the capabilities and capacity for preclinical and Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., fertility studies, pharmacology, toxicology, reproductive tract histopathology, sperm morphology). The purpose of this FOA is to provide investigators with a mechanism to request services from this facility that would advance their contraceptive development program....
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 1, 2019 Category: Research Source Type: funding
Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-261 from the NIH Guide for Grants and Contracts. The NICHD has a state-of-the-art Chemical Synthesis and Optimization Facility for advancing male and/or female non-hormonal contraception developmentwith the capabilities and capacity for preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism, fertility studies). The purpose of this FOA is to provide investigators with a mechanism to request services from...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 26, 2019 Category: Research Source Type: funding
Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet) (Admin Supp Clinical Trial Not Allowed)
Funding Opportunity PA-19-174 from the NIH Guide for Grants and Contracts. This administrative supplement funding opportunity announcement is part of the Beau Biden Cancer MoonshotSM Initiative to accelerate cancer research and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the National Cancer Institute (NCI) created the Patient-Derived Xenograft (PDX) Development and Trial Centers Research N...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 29, 2019 Category: Research Source Type: funding
